Vitamin B12

Why It Matters for Longevity

Vitamin B12 deficiency is a specific risk for vegans and the elderly even on high-nourishment diets. B12 is found almost exclusively in animal foods; essential for neurological function, DNA synthesis, and red blood cell formation. Absorption decreases with age due to reduced intrinsic factor secretion in the stomach. B12 deficiency has been implicated in brain aging and dementias; Alzheimer's patients have lower levels of folate and vitamin B12. B12 is required for the conversion of homocysteine to methionine; elevated homocysteine is a risk factor for neurodegeneration and cardiovascular disease. Longo explicitly recommends a complete multivitamin and mineral pill every three days to prevent B12 deficiency, especially for those on plant-based diets. Supplemental B12 bypasses the intrinsic factor dependency when taken in high-dose forms (cyanocobalamin or methylcobalamin), ensuring adequate status.

Mechanism: Homocysteine and One-Carbon Metabolism

B12 functions as a cofactor for two enzymes: methionine synthase and methylmalonyl-CoA mutase. Methionine synthase transfers a methyl group from 5-methyltetrahydrofolate to homocysteine, regenerating methionine and keeping homocysteine levels low. Methylmalonyl-CoA mutase converts methylmalonyl-CoA to succinyl-CoA, a step in odd-chain fatty acid catabolism and propionate disposal. When B12 status falls, both pathways slow: homocysteine accumulates in plasma, and methylmalonic acid (MMA) rises in blood and urine. Plasma MMA is a more specific marker of cellular B12 deficiency than serum B12 alone, because serum B12 can be normal while intracellular enzyme activity is already impaired.

Elevated homocysteine is not merely a biomarker. Smith and Refsum's comprehensive 2016 review in the Annual Review of Nutrition examined the evidence that elevated homocysteine from B12 and folate deficiency accelerates brain atrophy and cognitive decline, acting through several mechanisms: increased oxidative stress, endothelial dysfunction, and direct neurotoxicity. The review identified plasma homocysteine above ~12 µmol/L as a modifiable risk factor for brain aging, consistent with the accelerated atrophy seen in deficient individuals.

Brain Atrophy: Evidence from the VITACOG Trial

The most direct clinical test of the B12-brain atrophy hypothesis is the VITACOG trial (Smith et al., 2010), a randomized, double-blind, placebo-controlled trial in 168 adults over 70 years old with mild cognitive impairment. Participants received high-dose folic acid (0.8 mg/day), B12 (0.5 mg/day), and B6 (20 mg/day), or placebo for 24 months, with MRI brain volume measured at baseline and endpoint. The treatment group showed annual brain atrophy of 0.76% versus 1.08% in placebo — a 29.6% reduction in atrophy rate (p=0.001). Among participants with baseline homocysteine above 13 µmol/L, atrophy was 53% lower in the active group (p=0.001). The benefit was concentrated in those with elevated homocysteine at baseline, suggesting the intervention works specifically by correcting a deficiency state rather than providing a pharmacological effect in replete individuals.

Absorption Decline With Age and the Intrinsic Factor Problem

The elderly face a compound absorption problem. First, gastric acid secretion declines with age (atrophic gastritis affects an estimated 10–30% of people over 60), reducing the release of food-bound B12 from protein. Second, autoimmune destruction of gastric parietal cells can eliminate intrinsic factor production entirely (pernicious anemia), making dietary B12 effectively unabsorbable regardless of intake. Baik and Russell's 1999 review documented that food-cobalamin malabsorption — the inability to cleave B12 from food protein — is the most common cause of B12 deficiency in older adults, distinct from the dietary insufficiency that drives deficiency in vegans. High-dose cyanocobalamin (1000 mcg/day orally) partially bypasses this problem: approximately 1% of a large oral dose is absorbed by passive diffusion through the gut wall, independent of intrinsic factor, providing roughly 10 µg/day of absorbed B12 even in individuals with absent intrinsic factor.

Metformin Depletion: A Clinically Relevant Drug Interaction

Metformin, the most widely prescribed antidiabetic drug globally, reduces vitamin B12 levels through a mechanism involving calcium-dependent membrane action in the ileum that impairs intrinsic factor-mediated B12 absorption. A meta-analysis of six RCTs by Liu et al. (2014) quantified the effect: metformin reduced serum B12 by a mean of 53.93 pmol/L (95% CI: −81.44 to −26.42, p=0.0001) compared to placebo or active comparator. The depletion was dose-dependent: patients taking ≥2,000 mg/day showed a mean reduction of 78.62 pmol/L versus 37.99 pmol/L at lower doses. The prevalence of clinical deficiency in metformin-treated patients across studies ranges from 6% to 30%, with borderline-low status (a larger group) representing additional risk. Given the overlap between type 2 diabetes, aging, and neurological risk, unmonitored B12 depletion by metformin may quietly worsen the cognitive trajectory the drug otherwise aims to protect.

How to Use It

Pairs well with clams, salmon, sardines. Use as a nutrient in your daily meals according to the Longevity Diet guidelines.

What to Pair It With

Synergies

• Folate (synergy): B12 and folate act together in the one-carbon metabolism cycle; combined deficiency causes elevated homocysteine and macrocytic anemia. Both are flagged as deficiency risks in the book.
• Fish (synergy): Fatty fish (clams, salmon, sardines) are the most bioavailable dietary B12 sources and are the cornerstone protein in the Longevity Diet, providing B12 alongside omega-3 and vitamin D.
• Vitamin D (complement): Both nutrients are flagged as commonly deficient in aging and plant-based populations; Longo recommends co-supplementation via a multivitamin every 2–3 days.

Flavor Profile

Category: supplement/nutrient.

The Science

• Smith & Refsum, 2016, Annu Rev Nutr: Comprehensive review confirming that elevated homocysteine from B12/folate deficiency accelerates brain atrophy and cognitive decline, consistent with the book's claim linking low B12 to dementia risk.
• Baik & Russell, 1999, Annu Rev Nutr: Reviews prevalence and mechanisms of vitamin B12 deficiency in the elderly, including the role of reduced intrinsic factor and food-cobalamin malabsorption.
• Smith et al., 2010, PLoS One: VITACOG RCT (n=168, 24 months): B12/folate/B6 supplementation reduced brain atrophy rate by 29.6%; participants with homocysteine >13 µmol/L showed 53% less atrophy in treated versus placebo group.
• Liu et al., 2014, PLoS One: Meta-analysis of 6 RCTs found metformin reduced serum B12 by 53.93 pmol/L versus controls (p=0.0001), with depletion dose-dependent: −78.62 pmol/L at ≥2,000 mg/day.

References

1. Smith AD, Refsum H. Homocysteine, B Vitamins, and Cognitive Impairment. Annu Rev Nutr. 2016;36:211-39. PMID: 27431367. doi:10.1146/annurev-nutr-071715-050947
2. Baik HW, Russell RM. Vitamin B12 deficiency in the elderly. Annu Rev Nutr. 1999;19:357-77. PMID: 10448529. doi:10.1146/annurev.nutr.19.1.357
3. Smith AD, Smith SM, de Jager CA, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One. 2010;5(9):e12244. PMID: 20838622. doi:10.1371/journal.pone.0012244
4. Liu Q, Li S, Quan H, Li J. Vitamin B12 status in metformin treated patients: systematic review. PLoS One. 2014;9(6):e100379. PMID: 24959880. doi:10.1371/journal.pone.0100379

Key Nutrients